NEW YORK, Oct. 11, 2018 — The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
OPKO Health Inc. (NASDAQ: OPK) Class Period: September 26, 2013 to September 7, 2018 Lead Plaintiff Deadline: November 13, 2018
OPKO Health Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) OPKO and its Chairman and Chief Executive Officer, Phillip Frost, were engaged in a pump-and-dump scheme with several other individuals and companies in their investments in several penny stocks; (2) this illicit scheme would result in governmental scrutiny including from the SEC; and (3) as a result, defendants’ statements about OPKO’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Get additional information about the OPK lawsuit: http://www.kleinstocklaw.com/pslra-1/opko-health-inc-loss-submission-form?wire=3
TG Therapeutics, Inc. (NASDAQCM: TGTX) Class Period: June 4, 2018 to September 25, 2018 Lead Plaintiff Deadline: December 3, 2018
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
According to the complaint, TG Therapeutics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) TG was involved in cleaning the data collected in the UNITY-CLL Trial; and as a result, was able to gain an understanding as to the efficacy of the combination therapy; (2) as a result of that data cleaning, TG knew the UNITY-CLL Trial had failed to meet its stated goal and as a result, the Company would not be able to seek accelerated approval; and (3) given that the UNITY-CLL Trial had failed to meet its stated goal, it was highly unlikely that the combination therapy would meet its primary endpoint of increased progression free survival.
Get additional information about the TGTX lawsuit: http://www.kleinstocklaw.com/pslra-1/tg-therapeutics-inc-loss-submission-form?wire=3
Hasbro, Inc. (NASDAQGS: HAS) Class Period: April 24, 2017 to October 23, 2017 Lead Plaintiff Deadline: November 27, 2018
The lawsuit alleges that throughout the class period, Hasbro, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Hasbro’s relationship with Toys “R” Us was becoming increasingly important to Hasbro’s business, as Toys “R” Us was the primary retail brick-and-mortar toy store in the United States; (2) Toys “R” Us was in far worse financial condition than was being publicly reported and it would have to dramatically scale back its operations or file for bankruptcy and liquidate; and (3) Hasbro was experiencing significant adverse sales issues in the key markets of the United Kingdom and Brazil which were negatively impacting the Company’s efforts to grow sales in those markets.
Get additional information about the HAS lawsuit: http://www.kleinstocklaw.com/pslra-1/hasbro-inc-loss-submission-form?wire=3
Campbell Soup Company (NYSE: CPB) Class Period: August 31, 2017 to May 17, 2018 Lead Plaintiff Deadline: November 27, 2018
Campbell Soup Company allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the defendants failed to disclose known trends that were negatively impacting the profitability of the Campbell Fresh division; and (2) as a result of the foregoing, the defendants’ positive statements about Campbell’s and the Campbell Fresh division’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.
Get additional information about the CPB lawsuit: http://www.kleinstocklaw.com/pslra-1/campbell-soup-company-loss-submission-form?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 [email protected] Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com